Lupin introduces triple combination Vilfuro-G in India for COPD

Pharmaceutical company Lupin has introduced the fixed-dose triple combination (FDC) drug, Vilfuro-G, to manage chronic obstructive pulmonary disease (COPD) in India.
Lupin’s Vilfuro-G blends fluticasone furoate, vilanterol and glycopyrronium bromide and is the world’s first FDC to manage and treat moderate to severe COPD on a long-term basis.
The company is offering the drug in a single-strength fixed dose, with a recommended dosage of once a day.
The product is expected to benefit 37 million people with COPD, a condition that is one of India’s primary causes of death and disability.
Lupin India region formulations president Rajeev Sibal stated: “As the global prevalence of COPD continues to surge, India bears a significant 18% of this disease burden.
“With our extensive respiratory portfolio and the approval of Vilfuro-G, we take immense pride in offering healthcare professionals and patients innovative treatment solutions.”
Source: Pharmaceutical-technology